Outlook Therapeutics, Inc.

NASDAQ:OTLK

Biotechnology

Healthcare
$0.41 -5.76%

-$0.10 today

Market cap
$99.30M
Beta
0.98
P/E (TTM)
-2.1
EPS (TTM)
-$0.74
52W Low $0.16High $3.39

Volume 4.42M

Average 17.46M

OTLK EBITDA Margin

EBITDA as a percentage of revenue.

Outlook Therapeutics, Inc.NASDAQ: OTLK

EBITDA Margin · Q2 FY2026 · quarter ended Mar 2026

EBITDA Margin at -10983.0%

EBITDA Margin was -10983.0% in Q2 FY2026. On a trailing-twelve-month basis it was -18634.1%, down 28166.9 pp year over year.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of -1477.9% for the fiscal year ending Sep 2026, up from -4497.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-10983.0%-12096.8 pp QoQ
Last fiscal yearSep 2025
-4497.7%— YoY
LTMMar 2026
-18634.1%-28166.9 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter—+203.3 pp—
1 year—+3019.8 pp—
3 years—+4505.6 pp—
5 years+4503.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-4497.7%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How OTLK compares with its peers on the latest reported figures

  • OTLK's LTM Mar 2026 EBITDA Margin of -18634.1% is the lowest of the 6 companies compared; the peer median is -104.8%.
  • Its year-over-year change of -28166.9 pp is the lowest of 4, against a peer median of +1695.0 pp.
OTLK Competitors Peer median
EBITDA Margin for OTLK and competitors
Company Period LTM level YoY 3-year change
IPSCCentury Therapeutics, Inc.FY20253.2% +1695.0 pp+2334.4 pp
CUECue Biopharma, Inc.LTM Mar 2026-48.4% +416.8 pp+3974.4 pp
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026-104.8% ——
COEPCoeptis Therapeutics, Inc.LTM Mar 2026-769.0% +15034.6 pp—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-1017.5% ——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-18634.1% -28166.9 pp—
SPRBSpruce Biosciences, Inc.FY2025— ——
EQEquillium, Inc.FY2025— ——
OSTXOS Therapies IncorporatedFY2025— ——
Peer median (excluding OTLK) -104.8%+1695.0 pp+3154.4 pp

Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00001.41M
Cost of Revenue262.14K204.69K44.19K113.86K756.33K
Gross Profit(262.14K)(204.69K)(44.19K)(113.86K)657.21K
Gross Margin————46.5%
Research & Development38.96M42.33M26.45M41.76M27.18T
Selling, General & Admin12.77M20.74M26.67M29.94M39.94M
Operating Expenses51.73M62.87M53.13M71.7M67.72M
Depreciation & Amortization262.14K204.69K44.19K113.86K117.05K
EBITDA(51.51M)(64.36M)(57.38M)(72.09M)(63.58M)
EBITDA Margin————-4497.7%
Operating Income(51.73M)(63.07M)(53.13M)(71.7M)(67.06M)
Operating Margin————-4744.3%
Interest Income000906.15K89.74K
Interest Expense936.13K1.49M1.56M3.16M283.13K
Other Income / Expenses(1.43M)(2.98M)(5.85M)(3.66M)3.08M
Income Before Tax(53.16M)(66.05M)(58.98M)(75.36M)(63.98M)
Pre-Tax Margin————-4526.0%
Income Tax Expense2K2.8K2.8K2.8K(1.55M)
Net Income(53.16M)(66.05M)(58.98M)(75.37M)(62.42M)
Net Margin————-4416.2%
EPS (Basic)(6.96)(6.23)(4.72)(4.06)(1.79)
EPS (Diluted)(6.96)(6.23)(4.72)(4.06)(1.79)
Weighted Avg Shares7.63M10.6M12.51M18.55M34.8M
Weighted Avg Shares (Diluted)7.63M10.6M12.51M18.55M25.48M

Outlook Therapeutics, Inc.

NASDAQ:OTLK

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.